Valuation: Norda ASA

Market Cap 51Cr 5.43Cr 4.74Cr 4.46Cr 4.07Cr 7.64Cr 519.04Cr 7.64Cr 54Cr 21Cr 265.06Cr 20Cr 20Cr 854.51Cr P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 26Cr 2.8Cr 2.44Cr 2.3Cr 2.1Cr 3.93Cr 267.38Cr 3.94Cr 28Cr 11Cr 136.54Cr 11Cr 10Cr 440.19Cr EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day-0.46%
1 week-0.46%
Current month+1.18%
1 month-0.46%
3 months-0.46%
6 months+1.06%
Current year-14.00%
1 month 85
Extreme 85
86.4
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 08/04/2013
Director TitleAgeSince
Chairman 54 31/01/2014
Director/Board Member 68 20/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-0.46%-0.46%+6.17%+109.76% 4.67Cr
-0.07%+4.38%+4.27%+30.06% 4.79TCr
+0.08%+0.16%+43.79%+35.89% 4.45TCr
+0.66%+6.23%+8.96%+93.14% 4.19TCr
+0.05%-5.86%+334.27%+542.87% 4.13TCr
-1.60%+0.56%+10.84%+46.93% 3TCr
+0.96%+1.56%+26.52%+159.67% 1.76TCr
-0.01%-0.92% - - 1.56TCr
-1.04%+4.58%+25.11%+42.71% 1.57TCr
-1.08%+12.11%-10.11% - 1.39TCr
Average -0.17%+2.58%+49.98%+132.63% 2.68TCr
Weighted average by Cap. -0.08%+2.14%+68.79%+143.45%

Financials

2023 2024
Net sales 8.69Cr 91.96L 80.37L 75.54L 68.93L 1.29Cr 88Cr 1.29Cr 9.07Cr 3.5Cr 45Cr 3.45Cr 3.38Cr 144.74Cr 37Cr 3.93Cr 3.44Cr 3.23Cr 2.95Cr 5.53Cr 376.11Cr 5.54Cr 39Cr 15Cr 192.07Cr 15Cr 14Cr 619.19Cr
Net income 3.12Cr 32.98L 28.82L 27.09L 24.72L 46.4L 32Cr 46.4L 3.25Cr 1.25Cr 16Cr 1.24Cr 1.21Cr 52Cr 13Cr 1.33Cr 1.16Cr 1.09Cr 99.88L 1.87Cr 127.39Cr 1.87Cr 13Cr 5.07Cr 65Cr 5Cr 4.89Cr 209.72Cr
Net Debt -31Cr -3.29Cr -2.88Cr -2.7Cr -2.47Cr -4.63Cr -314.8Cr -4.63Cr -32Cr -13Cr -160.76Cr -12Cr -12Cr -518.27Cr -25Cr -2.63Cr -2.3Cr -2.16Cr -1.97Cr -3.7Cr -251.66Cr -3.7Cr -26Cr -10Cr -128.52Cr -9.89Cr -9.67Cr -414.32Cr
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
Date Price Change Volume
16/26/16 NOK 86.00 -0.46% 40
  1. Stock Market
  2. Stocks
  3. NORD Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!